ERCC1 投稿.docVIP

ERCC1 codon118基因表达在预测三代含铂方案治疗晚期非小细胞肺癌疗效中的意义 摘要：目的：探讨ERCC1 codon118基因表达对预测三代含铂方案治疗晚期非小细胞肺癌疗效的影响。方法：对我院收治的329例晚期非小细胞肺癌患者进行ERCC1 codon118基因多样性检测，以及对各基因型对三代含铂方案治疗晚期非小细胞肺癌疗效进行比较。结果：C/C组与C/T组＋T/T组患者其肿瘤分化程度、临床分期、肿瘤大小、血管侵犯等基本资料无明显的相关性（p＞0.05）；C/C组患者其无进展生存时间以及生存时间、1年、2年以及3年生存率为13.2±5.4月、25.4±4.3 月、65.76%、21.20%以及13.59%，明显高于对照组的6.2±4.3月、10.5±3.2月、28.28%、7.59 2%、1.38%。结论：ERCC1 codon118基因表达可能与预测三代含铂方案治疗晚期非小细胞肺癌敏感性有关。 关键词：ERCC1；铂类；非小细胞肺癌 The ERCC1 codon118 gene expression significance in predicting the three generations of platinum-containing regimen in advanced non-small cell lung cancer Abstract: Objective: To investigate the the ERCC1 codon118 gene expression predict the three generations of platinum-containing regimen in advanced non-small cell lung cancer. Methods : In our hospital, 329 cases of patients with advanced non-small cell lung cancer of ERCC1 codon118 gene diversity detection, as well as compare genotypes third-generation platinum-containing regimen in advanced non-small cell lung cancer. Results: The C / C and C / T group + T / T patients the degree of tumor differentiation, clinical stage, tumor size, vascular invasion and other basic information was no significant correlation (p 0.05); C / C patients progression-free survival and survival time, 1 year, 2 years and 3 year survival rate was 13.2 ± 5.4 months, 25.4 ± 4.3 months, 65.76%, 21.20% and 13.59%, significantly higher than 6.2 ± 4.3 months, 10.5 ± 3.2 months, 28.28%, 7.59%, 1.38%. Conclusion: codon118 of ERCC1 gene expression may predict the three generations of platinum-containing regimen in advanced non-small cell lung cancer susceptibility. Keywords: ERCC1; platinum; non-small cell lung cancer 肺癌作为全世界发病率以及死亡率均最高的恶性肿瘤,其中非小细胞肺癌( non-small cell lung cancer, NSCLC)最为常见[1]。对晚期NSCLC的治疗主要采用含铂化疗方案进行治疗,但其可导致NSCLC细胞DNA的损伤,而一旦DNA发生损伤,细胞内存在DNA修复机制,在进行修复中, 核苷酸切除修复系统在DNA修复中发挥重要作用,而其核心是ERCC1 ( excision repair cross-complementation group 1)[2]。本临床研究为探究ERCC1基因表达在预测三代含铂方案治疗晚期非小细胞肺癌疗效的可能性进行分析，现将其报道如下： 1材料与方法 1.1临床资料 对我